COMMUNIQUÉS West-GlobeNewswire
-
Sanofi obtient un avis positif du CHMP pour son vaccin contre la dengue
19/10/2018 - 13:38 -
Integrated Cannabis Company, Inc. to Acquire Assets of Colorado-Based Cannabis Innovator, Critical Mass Industries, LLC, With an Estimated USD $7 Million in Annual Revenue
19/10/2018 - 13:30 -
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families
19/10/2018 - 13:30 -
MRI Interventions Signs Exclusive Distribution Agreement with Clinical Laserthermia Systems (CLS) for U.S. and Canada
19/10/2018 - 13:30 -
New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab
19/10/2018 - 13:05 -
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
19/10/2018 - 13:00 -
BeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Update Conference Call on October 23, 2018
19/10/2018 - 13:00 -
Orion Corporation: Managers' transactions - Sydäntutkimussäätiö sr.
19/10/2018 - 12:46 -
Digirad Corporation to Release 2018 Third Quarter Financial Results on November 2, 2018
19/10/2018 - 12:00 -
PCI Biotech to present Phase I dose escalation results at ESMO
19/10/2018 - 10:03 -
Immunicum AB (publ) Announces Nomination Committee for AGM 2019
19/10/2018 - 08:01 -
Rule 2.9 Announcement
19/10/2018 - 08:00 -
Oxurion NV Business Update - Q3 2018
19/10/2018 - 07:31 -
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
19/10/2018 - 07:16 -
Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares
19/10/2018 - 07:01 -
Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress
19/10/2018 - 07:01 -
ChemioCare Expands Proprietary Transdermal Platform
19/10/2018 - 02:11 -
BioTelemetry, Inc. to Release Third Quarter 2018 Earnings Results on October 30, 2018
19/10/2018 - 01:02 -
Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock
19/10/2018 - 00:03
Pages